Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 3/20 | 0.61 |
| ▸ | CTSK | P43235 | 3/20 | 0.61 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.61 |
| ▸ | CTSH | P09668 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 3/20 | 0.57 |
| ▸ | MC5R | P33032 | 2/20 | 0.57 |
| ▸ | MC3R | P41968 | 2/20 | 0.57 |
| ▸ | MC1R | Q01726 | 2/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.56 |
| ▸ | APLNR | P35414 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NMBR | P28336 | 2/20 | 0.50 |
| ▸ | GRPR | P30550 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427910 | 0.98 | C5AR1 (0.62) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL30427315 | 0.90 | C5AR1 (0.72) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL16455231 | 0.87 | C5AR1 (0.68) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL30800876 | 0.87 | C5AR1 (0.72) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL14552191 | 0.86 | CTSL (0.60) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL23660906 | 0.86 | CTSL (0.65) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL23660890 | 0.86 | CTSL (0.65) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL23660928 | 0.86 | CTSL (0.65) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL23660911 | 0.86 | CTSL (0.65) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL23660900 | 0.86 | CTSL (0.65) | CTSLCTSSCTSKC5AR1CTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057914-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240398891-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2024-12-05 | — | — | US | disclosed |
| US-11576987-B2 | Compositions and methods of treating melanoma | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220111080-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220072092-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057914-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, RB1 | CTSL 2951/4885CTSS 3599/4885CTSK 2344/4885 |
| US-20240398891-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, RB1 | CTSL 2959/4885CTSS 3568/4885CTSK 2332/4885 |
| US-20220072092-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, RB1 | CTSL 2951/4885CTSS 3599/4885CTSK 2344/4885 |
| US-11576987-B2 | Compositions and methods of treating melanoma | MC1R, TIE1, RB1 | CTSL 3001/4885CTSS 3601/4885CTSK 2333/4885 |
| US-20220111080-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, RB1 | CTSL 3001/4885CTSS 3601/4885CTSK 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.